Pursuant to Regulation 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that at the Board Meeting held today i.e. on Friday, ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
ANG Lifesciences India Limited's Board approved its audited financial results for Q4 FY25 and full year FY25 on May 30, 2025. Standalone revenue from operations fell sharply to ₹8,991.01 lakhs in FY25 from ₹13,136.88 lakhs in FY24, a decline of roughly 32%, while Q4 FY25 revenue dropped to ₹1,766.61 lakhs from ₹3,407.99 lakhs a year earlier. The company slipped deeper into the red, posting a standalone net loss of ₹1,034.29 lakhs (FY24: loss of ₹864.81 lakhs) and a consolidated net loss of ₹1,241.33 lakhs (FY24: loss of ₹1,014.30 lakhs), with standalone EPS at ₹(7.86). Total borrowings rose to about ₹6,780 lakhs (standalone) against equity of ₹6,680 lakhs, and operating cash flow was negative at ₹(229.27) lakhs standalone and ₹(422.67) lakhs consolidated. Statutory auditors M/s Khurana Sharma & Co. issued an unmodified opinion on the results.
This is a negative outcome for shareholders — revenue shrank by over 30%, losses widened, the company is now operating with debt exceeding its equity, and cash burn from operations continues. The stock is likely to face pressure on the back of weak results, though the clean (unmodified) auditor opinion removes any immediate corporate governance overhang.